KRAScendo 1, SAFFRON, CLARITY-Gastric 01 and HARMONi-GI1 will be presented at the ESMO26 Presidential Symposium II at 16:30 CET. The poster will share notes after each late-breaking abstract.
Key points
Presidential Symposium II (16: 30 CET) includes KRAScendo 1, SAFFRON, CLARITY-Gastric 01, HARMONi-GI1.
Notes will be posted right after each late-breaking abstract.
Sources
PERSEE phase III trial reshapes PD-L1 high therapy choices
PERSEE phase III trial reported convincing and impressive results for PD-L1 high patients, including ultra-high PD-L1 80/90%. The study was led by the GFPC group.
Key points
Phase III trial (PERSEE) results for PD-L1 high patients.
Includes ultra-high PD-L1 80/90% subgroup.